Safety, efficacy and pharmacokinetics of interferon alfa-2B and ribavirin in children with chronic hepatitis C.

被引：0
|
作者：
Bunn, S [1 ]
Kelly, D [1 ]
Murray, KF [1 ]
Shelton, M [1 ]
Olson, A [1 ]
Mieli-Vergani, G [1 ]
Zambas, D [1 ]
Gupta, SK [1 ]
Glue, P [1 ]
机构：
[1] Spri, Kenilworth, NJ USA
来源：
HEPATOLOGY | 2000年 / 32卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
763
引用
收藏
页码：350A / 350A
页数：1
相关论文
共 50 条
  • [31] Consensus Interferon and Ribavirin in Patients with Chronic Hepatitis C Who Were Nonresponders to Pegylated Interferon alfa-2b and Ribavirin
    Carroll B. Leevy
    Digestive Diseases and Sciences, 2008, 53 (7) : 2009 - 2009
  • [32] Combination therapy with interferon alfa-2b, ribavirin, and amantadine in chronic hepatitis C non-responders to interferon and ribavirin
    Pande, H
    Thuluvath, PJ
    Jaffer, SA
    Maygers, J
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (09): : S96 - S96
  • [33] EFFICACY AND SAFETY RESULTS OF ALBINTERFERON ALFA-2B IN COMBINATION WITH RIBAVIRIN IN INTERFERON-ALFA TREATMENT NAIVE PATIENTS WITH GENOTYPE 2 OR 3 CHRONIC HEPATITIS C
    Nelson, D.
    Benhamou, Y.
    Chuang, W. L.
    Lawitz, E.
    Flisiak, R.
    Rodriguez-Torres, M.
    Bain, V.
    Patel, K.
    Cronin, P. W.
    Pulkstenis, E.
    Subramanian, G. M.
    McHutchison, J. G.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S378 - S378
  • [34] Pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a or alfa-2b with ribavirin in treatment naive patients with genotype 1 chronic hepatitis C
    Di Bisceglie, AM
    Rustgi, VK
    Thuluvath, P
    Davis, M
    Ghalib, R
    Lyons, MF
    Ondovik, MS
    Lopez-Talavera, JC
    HEPATOLOGY, 2004, 40 (04) : 734A - 734A
  • [35] Long-term response to interferon alfa-2b in chronic hepatitis C.
    Kuziemski, A
    Topczewska-Staubach, E
    Pawlowska, M
    Olczak, A
    EUROPEAN CYTOKINE NETWORK, 1998, 9 (03) : 428 - 428
  • [36] Recombinant interferon alfa-2B treatment for chronic hepatitis C. Multicenter study
    Feher, J
    Lengyel, G
    Dalmi, L
    David, K
    Gervain, J
    Gogl, A
    Lonovics, J
    Ozsvar, Z
    Par, A
    Schneider, F
    Tulassay, Z
    HEPATOLOGY, 1996, 23 (01) : P121 - P121
  • [37] The Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.
    Fontaine, H
    Pol, S
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 1999, 23 (04): : 541 - 544
  • [38] Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy
    Lin, Hsien-Hong
    Hsu, Shih-Jer
    Lu, Sheng-Nan
    Chuang, Wan-Long
    Hsu, Chao-Wei
    Chien, Rong-Nan
    Yang, Sien-Sing
    Su, Wei-Wen
    Wu, Jaw-Ching
    Lee, Tzong-Hsi
    Peng, Cheng-Yuan
    Tseng, Kuan-Chiao
    Qin, Albert
    Huang, Yi-Wen
    Chen, Pei-Jer
    JGH OPEN, 2021, 5 (08): : 929 - 940
  • [39] Safety and efficacy of interferon alfa-2b and ribavirin combination therapy for the treatment of hepatitis C in patients coinfected with HIV.
    Bini, EJ
    Reid, M
    Mannix, RA
    Wu, B
    HEPATOLOGY, 2001, 34 (04) : 335A - 335A
  • [40] A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C
    Glue, P
    Rouzier-Panis, R
    Raffanel, C
    Sabo, R
    Gupta, SK
    Salfi, M
    Jacobs, S
    Clement, RP
    HEPATOLOGY, 2000, 32 (03) : 647 - 653
12345